Based on preclinical results showing its ability to target the p53 pathway by inhibiting MDMX and MDM2, ALRN-6924 is currently being evaluated in a phase 1 study as monotherapy and in combination with cytarabine for relapsed/refractory AML or IPSS-R intermediate-, high-, or very high-risk MDS with wild-type TP53 (NCT02909972 [113]). Here, TP53 is linked to myelodysplastic syndrome.